Advances in the Clinical Management of HIV Disease and Hepatitis C Virus Infection
New York, NY
Friday, October 20, 2017
Agenda and Speakers
The most important advances in the clinical management of HIV disease and hepatitis C virus infection in the last year will be summarized and presented by leading experts in the field, in a 1-day CME course setting.
Assessment of Needs
The IAS–USA will bring together HIV and HCV for one comprehensive day of CME. Learn about new developments in HIV treatment as well as the rapid advances in HCV management and its cure.
- Treatment of HIV/HCV coinfection
- Access current data on newly approved and investigational treatments
- Evaluate current treatment options in specific patient populations
On completion of the course, participants will be able to:
- Describe the most recent advances in antiretroviral therapy including initial regimens, switching therapy, and investigational new approaches
- Apply new research data to the prevention and management of HIV infection with antiretroviral therapy
- Describe the elements of and response to an increase in HIV and HCV infection among persons who inject drugs
- Describe how the central nervous system should be considered in the management of patients with HIV infection as it relates to a cure
- Describe the effect of HCV on the liver, recognize how to stage liver disease, and why it is important to accurately stage
- Formulate state-of-the-art strategies for managing hepatitis B virus infection
- Describe the current data on available HCV treatments, the emergence of drug resistance, and investigational and other treatment regimens
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Who Should Attend
This course is designed for physicians who:
- have a solid, working knowledge of HIV or HCV disease management
- provide comprehensive or specialty care for patients with HIV, HCV, or HIV/HCV coinfection
- are actively involved in HIV or HCV research
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed a week after the course minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
This course is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.
HIV GRANT SUPPORT
Gilead Sciences, Inc
Janssen Therapeutics, Inc
HCV GRANT SUPPORT
Gilead Sciences, Inc